SHL Telemedicine Ltd. (SWX:SHLTN)
1.200
-0.020 (-1.64%)
At close: Nov 28, 2025
SHL Telemedicine Revenue
SHL Telemedicine had revenue of $27.92M USD in the half year ending June 30, 2025, a decrease of -3.74%. This brings the company's revenue in the last twelve months to $56.83M, up 1.59% year-over-year. In the year 2024, SHL Telemedicine had annual revenue of $56.78M, down -0.52%.
Revenue (ttm)
$56.83M
Revenue Growth
+1.59%
P/S Ratio
0.44
Revenue / Employee
$108.04K
Employees
526
Market Cap
19.67M CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 56.78M | -296.00K | -0.52% |
| Dec 31, 2023 | 57.08M | -1.92M | -3.26% |
| Dec 31, 2022 | 59.00M | 9.42M | 18.99% |
| Dec 31, 2021 | 49.58M | 9.42M | 23.45% |
| Dec 31, 2020 | 40.16M | -1.72M | -4.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.49B |
| Novartis AG | 44.95B |
| Sandoz Group AG | 8.42B |
| Alcon | 8.12B |
| Lonza Group AG | 7.09B |
| Galenica AG | 4.03B |
| Sonova Holding AG | 3.85B |
| Galderma Group AG | 3.73B |
SHL Telemedicine News
- 1 year ago - DocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular Care - Business Wire
- 1 year ago - SHL Telemedicine GAAP EPS of -$0.24 misses by $0.07, revenue of $27.9M misses by $1.1M - Seeking Alpha
- 1 year ago - SHL Telemedicine to Appoint David Arnon as CEO of SHL Telemedicine - Business Wire
- 1 year ago - SHL Telemedicine Confirms Discussions Regarding a Possible Investment in its Israeli Activity - Business Wire
- 1 year ago - SHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood Test - Business Wire
- 1 year ago - SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft Launch - Business Wire
- 1 year ago - SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones - Business Wire
- 1 year ago - Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine's SmartHeart® in Post-ACS Patient Care - Business Wire